Search Results for “cancer” – Page 59 – media

FDA approves first cancer biosimilar

The US Food and Drug Administration(FDA) has approved Amgen’s Mvasi (bevacizumab-awwb) as a biosimilar to Roche/Genentech’s Avastin (bevacizumab) for the treatment of multiple types of cancer, making it the first biosimilar approved in the country for the treatment of cancer.
- Source: Pharmatimes
- 679
- September 18, 2017
biosimilar cancer FDA New Approvals
Cancer Startup Torque Therapeutics Nabs $21 Million and Sets Up Shop in Kendall Square

Torque Therapeutics has come out of stealth mode to launch with a $21 million Series A financing. It is looking to raise another $14 million, according to its filing with the U.S. Securities and Exchange Commission (SEC).
- Source: Biospace
- 809
- September 15, 2017
cell immune Series therapy
Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) has granted Checkpoint Therapeutics, Inc. (“Checkpoint”) (CKPT)'s Orphan Drug Designation to CK-101 (also known as RX518), the Company’s third-generation epidermal growth-factor receptor (EGFR) inhibitor, for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC).
- Source: finance.yahoo
- 499
- September 12, 2017
FDA inhibitor NSCLC
Merck to Acquire Rigontec, Expanding Cancer Immunotherapy Franchise

Merck & Co. has agreed to acquire Rigontec for up to €464 million (about $554 million), in a deal that will expand the cancer immunotherapy franchise of the Keytruda® (pembrolizumab) developer with a three-year-old Bonn University spinout whose technology targets the retinoic acid-inducible gene I (RIG-I) pathway.
- Source: genengnews
- 539
- September 11, 2017
acquisition immunotherapy Market Views RIG-I
Verastem’s Duvelisib Succeeds in Late-Stage Blood Cancer Study

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported positive top-line results from the Phase 3 DUO study evaluating the efficacy and safety of duvelisib, a first in class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Source: Spjnews
- 739
- September 8, 2017
cancer Clinical Trials CLL inhibitor SLL
EUSA bags EU approval for kidney cancer drug

The European Commission has licensed EUSA Pharma’s Fotivda for the management of adult patients with advanced kidney cancer across the European Union as well as Norway and Iceland.
- Source: open-medical
- 568
- August 30, 2017
cancer inhibitor kidney New Approvals
Cel-Sci raises $3.5m for head and neck cancer immunotherapy

Cel-Sci said today that for a Phase III trial of its investigational immunotherapy, it inked an agreement with institutional investors for a $3.5 million registered direct offering.
- Source: drugdeliverybusiness
- 523
- August 24, 2017
Clinical Trials Company Insight immunotherapy
Cynvenio Biosystems initiates breast cancer monitoring study in US

Cynvenio Biosystems has initiated a clinical study to evaluate its LiquidBiopsy ClearID test in combination with NK Score natural killer cell activity to monitor breast cancer patients in the US.
- Source: medicaldevice-network
- 554
- August 22, 2017
breast cancer Clinical Researches
New CUHK study shows early nasopharyngeal cancer detection with EBV DNA

Early asymptomatic nasopharyngeal carcinoma (NPC) will possibly be detectable by plasma Epstein-Barr virus (EBV) DNA analysis, according to a new study carried out by the Chinese University of Hong Kong (CUHK).
- Source: medicaldevice-network
- 517
- August 15, 2017
carcinoma MRI nasopharyngeal Researches
NICE turns down kidney cancer drugs

It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will be getting routine NHS access to Eisai’s Kisplyx or Eusa Pharma’s Fotivda, after cost regulators issued draft guidelines turning down their use.
- Source: pharmatimes
- 511
- August 15, 2017
cancer kidney Market Views NHS renal

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.